INmune Bio, Inc. (INMB)
INMB Stock Price Chart
Explore INmune Bio, Inc. interactive price chart. Choose custom timeframes to analyze INMB price movements and trends.
INMB Company Profile
Discover essential business fundamentals and corporate details for INmune Bio, Inc. (INMB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Feb 2019
Employees
13.00
Website
https://www.inmunebio.comCEO
David J. Moss
Description
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
INMB Financial Timeline
Browse a chronological timeline of INmune Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.19, while revenue estimate is $1.16m.
Earnings released on 7 May 2026
EPS came in at -$0.20 surpassing the estimated -$0.25 by +18.37%.
Earnings released on 30 Mar 2026
EPS came in at -$0.18 surpassing the estimated -$0.27 by +33.33%.
Earnings released on 30 Oct 2025
EPS came in at -$0.24 surpassing the estimated -$0.31 by +22.58%.
Earnings released on 7 Aug 2025
EPS came in at -$0.34 surpassing the estimated -$0.37 by +8.11%.
Earnings released on 8 May 2025
EPS came in at -$0.43 matching the estimated -$0.43, while revenue for the quarter reached $50.00k .
Earnings released on 27 Mar 2025
EPS came in at -$0.40 surpassing the estimated -$0.54 by +25.93%.
Earnings released on 31 Oct 2024
EPS came in at -$0.60 falling short of the estimated -$0.49 by -22.45%.
Earnings released on 1 Aug 2024
EPS came in at -$0.50 surpassing the estimated -$0.63 by +20.63%.
Earnings released on 9 May 2024
EPS came in at -$0.61 falling short of the estimated -$0.53 by -15.09%, while revenue for the quarter reached $14.00k , missing expectations by -53.33%.
Earnings released on 28 Mar 2024
EPS came in at -$0.47 falling short of the estimated -$0.44 by -6.82%, while revenue for the quarter reached $28.00k , missing expectations by -30.00%.
Earnings released on 1 Nov 2023
EPS came in at -$0.48 falling short of the estimated -$0.39 by -23.08%, while revenue for the quarter reached $43.00k , beating expectations by +7.50%.
Earnings released on 7 Aug 2023
EPS came in at -$0.36 surpassing the estimated -$0.40 by +10.00%, while revenue for the quarter reached $46.00k , beating expectations by +21.05%.
Earnings released on 3 May 2023
EPS came in at -$0.36 falling short of the estimated -$0.02 by -1.70k%, while revenue for the quarter reached $38.00k .
Earnings released on 2 Mar 2023
EPS came in at -$0.32 surpassing the estimated -$0.48 by +33.33%, while revenue for the quarter reached $97.00k .
Earnings released on 2 Nov 2022
EPS came in at -$0.43 surpassing the estimated -$0.59 by +27.12%, while revenue for the quarter reached $98.00k .
Earnings released on 3 Aug 2022
EPS came in at -$0.38 surpassing the estimated -$0.50 by +24.00%, while revenue for the quarter reached $16.00k .
Earnings released on 5 May 2022
EPS came in at -$0.39 surpassing the estimated -$0.60 by +35.00%, while revenue for the quarter reached $163.00k , missing expectations by -28.09%.
Earnings released on 3 Mar 2022
EPS came in at -$0.55 surpassing the estimated -$0.56 by +1.79%, while revenue for the quarter reached $163.00k .
Earnings released on 3 Nov 2021
EPS came in at -$0.55 falling short of the estimated -$0.43 by -27.91%, while revenue for the quarter reached $14.00k , missing expectations by -98.56%.
Earnings released on 4 Aug 2021
EPS came in at -$0.44 falling short of the estimated -$0.33 by -33.33%.
INMB Stock Performance
Access detailed INMB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
